Guardian Partners Inc. Invests $9.16 Million in Sanofi (NASDAQ:SNY)

Guardian Partners Inc. purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 186,109 shares of the company's stock, valued at approximately $9,162,000.

Other institutional investors have also made changes to their positions in the company. Abel Hall LLC grew its stake in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after buying an additional 194 shares in the last quarter. Keudell Morrison Wealth Management boosted its position in shares of Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after acquiring an additional 217 shares in the last quarter. Bailard Inc. increased its stake in Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after acquiring an additional 220 shares during the last quarter. Old Port Advisors raised its position in Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company's stock valued at $1,770,000 after purchasing an additional 232 shares in the last quarter. Finally, ORG Partners LLC lifted its stake in Sanofi by 17.7% during the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company's stock worth $81,000 after purchasing an additional 253 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SNY has been the topic of several recent analyst reports. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Remove Ads

Sanofi Trading Up 0.8 %

Sanofi stock traded up $0.41 during trading hours on Thursday, hitting $54.91. The stock had a trading volume of 1,320,100 shares, compared to its average volume of 2,262,514. The stock has a market cap of $139.35 billion, a price-to-earnings ratio of 22.05, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The business's 50 day simple moving average is $55.03 and its 200-day simple moving average is $52.85. Sanofi has a one year low of $45.22 and a one year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.